Navigation Links
Cohera Medical Secures $16.1 Million in Series B Financing
Date:10/17/2008

PITTSBURGH, Oct. 17 /PRNewswire/ -- Cohera Medical Inc. today announced it has secured $16.1 million in a Series B financing for the ongoing development of TissuGlu(R), a novel surgical adhesive for application in plastic surgery.

The financing, which was led by Bradford Capital Partners, included participation from existing investors led by Kern Whelan Capital, LLC. The angel financing provides the company with sufficient capital to advance TissuGlu into clinical trials, which are expected to begin early next year.

"Kern Whelan Capital is delighted to support this second round of financing by doubling our initial investment," said Jay Kern, operating partner. "We believe there is a huge market potential in many applications for Cohera's products."

"TissuGlu has great promise in tummy tuck and other plastic surgery indications," said Marty Calihan, partner, Bradford Capital Partners. "Moreover, the company's core technology has significant potential for other uses, including mesh fixation and orthopedic applications. We view Cohera Medical's unique lead product and technology chassis as having tremendous potential to meet multiple needs of surgeons and their patients for which there are few options today."

Patrick Daly, chief executive officer of Cohera Medical, said "Our closing of this significant angel financing round in the current economic environment is a testament to the potential of our surgical adhesive technology. The financing gives us the capital to move forward with our clinical program for TissuGlu and affords us the opportunity to continue development of our other products."

About Cohera Medical

Cohera Medical Inc. is a Pittsburgh-based company that is developing a revolutionary line of wound management products and surgical adhesives. Cohera Medical's products are based on a unique chemical design that is purely synthetic, easy to use, biocompatible and fully resorbable. The company's lead product in development, TissuGlu, is a sprayable bonding agent for plastic surgery procedures. TissuGlu adheres flaps of tissue after surgical procedures, eliminating the spaces where fluid accumulates and reducing wound drainage. Cohera Medical is also developing surgical adhesives targeting mesh fixation and small bone fixation, which will fill similar market needs in both orthopedics and general surgery. For more information, visit http://www.coheramed.com. TissuGlu and the other Cohera products have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or by any other country's regulatory authority.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.


'/>"/>
SOURCE Cohera Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cohera Medical Names Richard L. Wonsettler as Companys First CFO
2. Data Published in Plastic and Reconstructive Surgery Show Cohera Medicals Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model
3. KePROs Chief Medical Officer to Present and Participate in Physician Roundtable at McKesson Health Solutions Conference
4. InHealth awards grants to study impact of medical diagnostics and devices on patients, health care
5. Clinicians in Netherlands Treat Lung Cancer Patients Using New RapidArc Radiotherapy Technology from Varian Medical Systems
6. Houston Northwest Medical Center Receives Clinical Excellence Awards for Several Service Lines
7. LegalView Reintroduces its Medical Malpractice Information Portal with Updated Links to Finding Immediate Legal Assistance
8. Sutter Medical Center Breaks Ground on Historic Womens and Childrens Center
9. Integrated Medical Systems Receives FDA Clearance for Worlds First Suitcase Intensive Care Unit
10. Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology
11. Geisinger Medical Center earns prestigious Magnet designation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... ... The weather is heating up and the days are getting longer, providing ... that the summer months provide more than warmer temperatures that are perfect for BBQ’s ... affected from direct exposure to the sun. When it comes to the security of ...
(Date:6/23/2017)... Beach, CA (PRWEB) , ... June 23, 2017 , ... ... has earned its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, ... in the top 1% of all charities reviewed by Charity Navigator and earns ANRF ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... practicing in Newburgh, New York, has recently begun offering three new minimally invasive ... the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited to bring ...
(Date:6/23/2017)... ... , ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s unique approach ... proprietary technique that he calls the AuraLyft Facelift. The AuraLyft does more ... can expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s unique approach ...
(Date:6/23/2017)... ... June 23, 2017 , ... MD Now Urgent Care opened its ... facility overall and marks the urgent care center's eighth location in Miami-Dade county. , ... Falls shopping mall. The new clinic offers a wide array of services ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  StatLab Medical ... developer and manufacturer of diagnostic supplies for ... that Cressey & Company LP ("Cressey & ... completed a growth-focused investment in the Company. ... ownership position from selling shareholder, Prairie Capital, ...
(Date:6/7/2017)... Iowa , June 6, 2017  Diplomat Specialty Infusion Group, ... sterile compounding environment to its Iowa location. ... Urbandale now features an ISO 7 cleanroom—the standard ... controlled environment with a low level of pollutants. ... more IV nutrition consumers and better serve our Iowa ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology: